Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment
- 22 November 2018
- journal article
- research article
- Published by Springer Nature in Hormones
- Vol. 17 (4) , 573-579
Abstract
The evaluation of (a) noggin levels in patients with simple steatosis (SS) vs. nonalcoholic steatohepatitis (NASH) vs. controls, and (b) the effect of combined spironolactone plus vitamin E vs. vitamin E monotherapy on noggin levels in biopsy-proven patients with nonalcoholic fatty liver disease (NAFLD).Keywords
This publication has 30 references indexed in Scilit:
- Inhibition of Bone Morphogenic Protein 4 Restores Endothelial Function in db/db Diabetic MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2014
- The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2013
- Bone Morphogenic Protein-4 Contributes to Venous Endothelial Dysfunction in Patients With Diabetes Undergoing Coronary RevascularizationThe Annals of Thoracic Surgery, 2013
- Glucose Utilization, Lipid Metabolism and BMP-Smad Signaling Pathway of Porcine Intramuscular Preadipocytes Compared with Subcutaneous PreadipocytesCellular Physiology and Biochemistry, 2013
- The WNT Inhibitor Dickkopf 1 and Bone Morphogenetic Protein 4 Rescue Adipogenesis in Hypertrophic Obesity in HumansDiabetes, 2012
- Nonalcoholic Fatty Liver DiseaseJournal of Clinical Gastroenterology, 2012
- Noggin Is Novel Inducer of Mesenchymal Stem Cell AdipogenesisJournal of Biological Chemistry, 2012
- NogginThe International Journal of Biochemistry & Cell Biology, 2011
- Bone Morphogenic Protein-4 Induces Hypertension in MiceCirculation, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005